Equipment Purchase Grants & Rebates in Australia (2026)

An equity co-investment venture capital program that provides early-stage biomedical companies with investment to develop and commercialise biomedical discoveries. The fund supports therapeutic, medical, pharmaceutical products, processes, services, technologies and procedures that improve health and wellbeing through prevention, diagnosis and treatment.

A $500 million funding program announced in the 2024-2025 Federal Budget to promote the development of battery manufacturing capabilities in Australia. The initiative provides capital grants, production incentives, or other payments to fund projects that enhance Australia's battery manufacturing capability and commercialise battery manufacturing processes and technologies that contribute to emissions reduction.

The Biomedical Translation Fund provides capital to support groundbreaking innovation in Australia, helping commercialize research from universities and research organizations into commercial products. The fund pools $500 million in total capital ($250 million from the federal government and $250 million from private investors) to support venture capital managers in taking Australian biomedical innovations through the commercial pathway.

A program that provides fund managers and investors with support to stimulate early stage venture capital investments. Fund managers can raise venture capital funds between $10 million and $200 million to invest in innovative early stage businesses, while both fund managers and investors receive tax benefits including exemptions on income and gains from eligible investments.

The 2026 BioMedTech Grant Opportunity is part of the Medical Research Future Fund under the Medical Research Commercialisation Initiative. This opportunity looks to fund suitable organisations to identify, select and support Australian SMEs undertaking early-stage medical research and medical innovation projects that have commercial potential. The intended outcome of the research funded by this grant opportunity is to improve the health and wellbeing of Australians by increasing the number of SMEs developing novel biomarkers, diagnostics, therapeutics, assistive devices and/or digital technologies that have progressed through the early stages of research and development to the point where they are 'de-risked' and attractive to private investment for commercialisation. Applicants may propose to support development of innovations in their area/s of strength (i.e. applicants are not required to propose a program that covers the breadth of the biomedtech sector). Eligibility: You can apply

The RJED Program seeks to fund 3,000 new jobs over 3 years to support job seekers currently participating in or that are eligible for Remote Australia Employment Services (RAES), to move into employment. There are two streams of funding available, Job Creation – to fund the cost of wages and related entitlements, and the Community Jobs and Business Fund (CJBF) – to provide funding for equipment, operational costs and infrastructure to directly support bringing jobs created under the Job Creation stream into existence. For the purposes of the RJED program, a new job is: •a job which does not already exist within an organisation and does not displace an existing employee, or •a job created in a RAES Community Project. As job allocations are based on NIAA regions, you will need submit a separate application for each NIAA region where you intend to deliver a job. For example: If you apply for jobs located in more than one RAES region, but all those jobs are in the same NIAA region, you wil